ApiJect Systems, Corp.

ApiJect Systems, Corp. provides innovative drug delivery solutions focusing on aseptic filling technology, aiming to enhance safety and efficiency in administering medications through its proprietary prefilled injector systems. ApiJect Systems, Corp. is known for its Blow-Fill-Seal (BFS) technology that combines a container with a pen needle hub for drug delivery.

Founded in 2016, the company is headquartered in Stamford, US. The co-founders include Jay Walker and Marc Koska, with Walker serving as the CEO. In May 2022, ApiJect raised USD 111 mn in a Secondary Stock Purchase funding round, co-led by Jefferies and Royalty Pharma, bringing its total valuation to USD 300 mn. ApiJect specializes in innovative drug delivery solutions through its core product, the Apiject Platform, which combines a Blow-Fill-Seal (BFS) container with a proprietary pen needle hub.

This system is designed to facilitate the aseptic filling of single-dose containers, ensuring safety and reliability in drug administration. The prefilled injector simplifies the injection process, making it suitable for various medical applications, particularly for conditions requiring regular injections such as diabetes management or vaccinations. The company targets a global market, focusing on regions with high demand for efficient drug delivery systems, including North America, Europe, and emerging markets in Asia, serving pharmaceutical companies, healthcare providers, and patients. ApiJect's revenue model is based on partnerships and B2B transactions with pharmaceutical companies and healthcare providers.

The company generates revenue through the sale of its prefilled injector systems and related products, typically through direct sales agreements focusing on large orders. While specific pricing plans are not disclosed, the structured sales approach likely involves negotiation of bulk pricing based on order volume and long-term contracts to ensure consistent supply for their clients. In May 2022, ApiJect Systems, Corp. raised USD 111 mn in venture funding to support the development of its Blow-Fill-Seal (BFS) plastic prefilled injection system.

The company plans to leverage this funding to enhance product offerings and expand into new markets. ApiJect is targeting growth in North America and Europe while exploring opportunities in emerging markets in Asia. Specific timelines for product launches or market entries have not been disclosed.